Panavance Therapeutics Inc. is a US, clinical-stage pharmaceutical company established in 2021 by the Swiss-based Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie. Panavance is focused on advancing the development of GP-2250, a novel oncology therapeutic intended to improve outcomes and quality of life for patients with cancer.

With its highly capable team and strong academic and industry partnerships, Panavance is pursuing a rigorous program to bring GP-2250 to patients around the world.

Life Sciences

Pharmaceutical

Therapeutics

Panavance Therapeutics Inc.

Greg Bosch

Thomas P. Hess

Tom Hess

José Iglesias

Ben Steinmetz

The Scientific and Research Team at Panavance Therapeutics Inc. is responsible for driving the advancement of GP-2250. Comprising experts in CMC (Chemistry, Manufacturing, and Controls), non-clinical research, pharmacology, and regulatory communications, the team conducts rigorous research, ensures quality control, navigates regulatory landscapes, and collaborates with academic and industry partners to bring innovative oncology therapies to patients globally.

Scientific and Research Team

Leadership Team

Scientific and Research Team

About

Team members

Other teams at Panavance Therapeutics Inc.

Leadership Team